| Dr Chad M Bentsen, MD | |
|
12040 Ne 128th St, Kirkland, WA 98034-3013 | |
| (425) 899-1000 | |
| Not Available |
| Full Name | Dr Chad M Bentsen |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 12040 Ne 128th St, Kirkland, Washington |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134174923 | NPI | - | NPPES |
| 185367 | Other | WA L&I | |
| 3350BE | Other | REGENCE BS | |
| 8272676 | Medicaid | WA | |
| H33675 | Other | GROUP HEALTH | |
| 8938301 | Other | WA CRIME VICTIM |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | MD00038520 (Washington) | Primary |
| Entity Name | King County Public Hospital District No 2 |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801986070 PECOS PAC ID: 7618880097 Enrollment ID: O20031111000557 |
News Archive
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that it has received preliminary results from a Phase II clinical trial of GDC-0449 from Roche and Genentech, Curis' collaborator and a member of the Roche Group.
Dr. Richard Dolinar, chairman of the Alliance for Safe Biologic Medicines (Alliance) outlined five areas of concern that the U.S. Food and Drug Administration (FDA) should resolve before they allow biosimilar medications on the U.S. drug market in prepared testimony for the FDA's May 11th public hearing. The event addressed the FDA's recent draft guidelines for the development of biosimilar products.
Tuberculosis remains one of the biggest killers in the world today being responsible for nearly ten million cases and one and a half million deaths each year.
An online COVID-19 symptom tracking tool developed by researchers at Georgetown University Medical Center ensures a person's confidentiality while being able to actively monitor their symptoms.
› Verified 7 days ago
| Entity Name | Evergreen Emergency Services Ps |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619912524 PECOS PAC ID: 4981694155 Enrollment ID: O20040518000743 |
News Archive
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that it has received preliminary results from a Phase II clinical trial of GDC-0449 from Roche and Genentech, Curis' collaborator and a member of the Roche Group.
Dr. Richard Dolinar, chairman of the Alliance for Safe Biologic Medicines (Alliance) outlined five areas of concern that the U.S. Food and Drug Administration (FDA) should resolve before they allow biosimilar medications on the U.S. drug market in prepared testimony for the FDA's May 11th public hearing. The event addressed the FDA's recent draft guidelines for the development of biosimilar products.
Tuberculosis remains one of the biggest killers in the world today being responsible for nearly ten million cases and one and a half million deaths each year.
An online COVID-19 symptom tracking tool developed by researchers at Georgetown University Medical Center ensures a person's confidentiality while being able to actively monitor their symptoms.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Chad M Bentsen, MD File 50421, Los Angeles, CA 90074-0001 Ph: (800) 793-3529 | Dr Chad M Bentsen, MD 12040 Ne 128th St, Kirkland, WA 98034-3013 Ph: (425) 899-1000 |
News Archive
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that it has received preliminary results from a Phase II clinical trial of GDC-0449 from Roche and Genentech, Curis' collaborator and a member of the Roche Group.
Dr. Richard Dolinar, chairman of the Alliance for Safe Biologic Medicines (Alliance) outlined five areas of concern that the U.S. Food and Drug Administration (FDA) should resolve before they allow biosimilar medications on the U.S. drug market in prepared testimony for the FDA's May 11th public hearing. The event addressed the FDA's recent draft guidelines for the development of biosimilar products.
Tuberculosis remains one of the biggest killers in the world today being responsible for nearly ten million cases and one and a half million deaths each year.
An online COVID-19 symptom tracking tool developed by researchers at Georgetown University Medical Center ensures a person's confidentiality while being able to actively monitor their symptoms.
› Verified 7 days ago
Austin M Gross, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 12040 Ne 128th St, Kirkland, WA 98034 Phone: 425-899-1711 | |
Dr. Wade W Webster, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 12040 Ne 128th St, Kirkland, WA 98034 Phone: 425-899-1000 | |
Dr. Dominic Connolly, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 12040 Ne 128th St, Kirkland, WA 98034 Phone: 425-899-1000 | |
Dr. Larisa A Kaukonen, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 12040 Ne 128th St, Kirkland, WA 98034 Phone: 425-899-1000 | |
Dr. Ronald Cole Dobson, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 8315 Ne Juanita Dr, Kirkland, WA 98034 Phone: 206-718-4072 Fax: 206-215-6599 | |
Dr. Adrian M Whorton, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 12040 Ne 128th St, Kirkland, WA 98034 Phone: 425-899-1000 |